These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38407898)

  • 1. Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):351-358. PubMed ID: 38407898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis.
    Mantovani A; Morandin R; Fiorio V; Lando MG; Petta S; Ferraro PM; Targher G
    Intern Emerg Med; 2024 Jul; ():. PubMed ID: 38992323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
    Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
    Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies.
    Zhang Y; Zhou BG; Zhan JD; Du BB
    Front Oncol; 2024; 14():1366195. PubMed ID: 38567158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies.
    Zhao JF; Zhou BG; Lv Y; Teng QP; Wang XM; Li XY; Ding Y
    Front Oncol; 2024; 14():1368965. PubMed ID: 39045565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modifiable risk factors for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease: a meta-analysis.
    Xiao S; Liu Y; Fu X; Chen T; Xie W
    Am J Med; 2024 Jul; ():. PubMed ID: 39047929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis.
    Mantovani A; Lando MG; Borella N; Scoccia E; Pecoraro B; Gobbi F; Bisoffi Z; Valenti L; Tilg H; Byrne CD; Targher G
    Liver Int; 2024 Jul; 44(7):1513-1525. PubMed ID: 38567962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis.
    Lv Q; Zhao H
    Ann Med; 2024 Dec; 56(1):2306192. PubMed ID: 38253023
    [No Abstract]   [Full Text] [Related]  

  • 11. Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality.
    Kim D; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A
    J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38740513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis.
    Mantovani A; Csermely A; Bilson J; Borella N; Enrico S; Pecoraro B; Shtembari E; Morandin R; Polyzos SA; Valenti L; Tilg H; Byrne CD; Targher G
    Gut; 2024 May; ():. PubMed ID: 38782564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing Liver Fibrosis in Type 2 Diabetes Mellitus Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: The Role of Non-invasive Scoring Systems and Associated Factors.
    Naskar A; Mondal A; Chatterjee R; De RD; Roy S
    Cureus; 2024 Jun; 16(6):e62405. PubMed ID: 39011198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
    Qi X; Li J; Caussy C; Teng GJ; Loomba R
    Hepatology; 2024 May; ():. PubMed ID: 38722246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipocytokines as Predictors of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development in Type 2 Diabetes Mellitus Patients.
    Fajkić A; Jahić R; Hadžović-Džuvo A; Lepara O
    Cureus; 2024 Mar; 16(3):e55673. PubMed ID: 38455340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease.
    Min Y; Wei X; Wei Z; Song G; Zhao X; Lei Y
    Cardiovasc Diabetol; 2024 Jun; 23(1):188. PubMed ID: 38824550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Kumar J; Mohsin S; Hasan M; Bilal AR; Ali KM; Umer A; Hadi DZM; Nandlal S; Kumar S
    Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102261. PubMed ID: 38070828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis.
    Nso N; Mergen D; Ikram M; Macrinici V; Hussain K; Lee K; Ugwendum D; Trimingham M; Balasubramanian S; Sam R; Njei B
    Curr Probl Cardiol; 2024 Jun; 49(6):102569. PubMed ID: 38599554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.